# IRON catalysts: Disc Medicine, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/iron/catalysts

> Disc Medicine, Inc. (IRON) has 6 upcoming catalysts. The next is the Disc Medicine, Inc. topline data readout, early 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for IRON?

Disc Medicine, Inc. (IRON) has 6 upcoming catalysts. The next is the Disc Medicine, Inc. topline data readout, early 2027. Press release filed with the SEC (EX-99): "Continue enrollment of the global, confirmatory APOLLO study with topline data expected by early 2027" [Calendar and source filings](https://sec-api.dev/companies/iron/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-009871, https://www.sec.gov/Archives/edgar/data/1816736/000119312526009871/iron-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-01-12. Cite: https://sec-api.dev/companies/iron/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Disc Medicine, Inc. |
| Ticker | IRON (Nasdaq) |
| SEC CIK | 1816736 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/iron |

## Cash runway

Cash $682.8M as of 2026-09-30; quarterly burn $40.2M; about 51.0 months of runway at that rate (XBRL company facts, accession 0001193125-26-448729).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2022 | [Bitopertin trial start](https://sec-api.dev/pdufa/bitopertin) | IRON |  | completed | "For example, we filed an IND in April 2022 with the FDA to initiate the AURORA Phase 2 trial of bitopertin in EPP patients, but the FDA initially placed the initiation of this trial on clinical hold; we received clearance to initiate the study in July 2022 after the study design was finalized with the FDA, and we initiated the study in October 2022." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1816736/000119312525268200/iron-20250930.htm)) |
| Jun 2022 | [Selcodebart trial start](https://sec-api.dev/pdufa/selcodebart) | IRON | anemia of different inflammatory diseases | completed | "Based on these findings, we initiated two Phase 1b/2 clinical trials of DISC-0974 in patients with anemia of different inflammatory diseases: a Phase 1b/2 clinical trial of DISC-0974 in patients with anemia of MF, which was initiated in June 2022, and a separate Phase 1b/2 clinical trial of DISC-0974 in patients with non-dialysis dependent CKD and anemia, which was initiated in February 2023." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1816736/000095017025028390/iron-20241231.htm)) |
| Feb 2023 | [Selcodebart trial start](https://sec-api.dev/pdufa/selcodebart) | IRON |  | completed | "In February 2023, we initiated a Phase 1b clinical trial to evaluate the safety, tolerability and efficacy of DISC-0974 in patients with CKD who are not receiving dialysis and are anemic." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm)) |
| Oct 2023 | [DISC-3405 trial start](https://sec-api.dev/pdufa/disc-3405) | IRON |  | completed | "In October 2023, the Company dosed the first patient in the Phase 1 clinical trial for DISC-3405, resulting in a milestone payment of $5.0 million to Mabwell." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1816736/000119312525268200/iron-20250930.htm)) |
| late 2024 | [Selcodebart trial start](https://sec-api.dev/pdufa/selcodebart) | IRON |  | scheduled | "The Company expects to initiate a Phase 2 study in anemia of myelofibrosis (MF) by the end of 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312524255200/d911918dex991.htm)) |
| November 12, 2024 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312524255200/d911918dex991.htm)) |
| Dec 2024 | [Selcodebart trial start](https://sec-api.dev/pdufa/selcodebart) | IRON | anemia of MF | completed | "In December 2024, we initiated RALLY-MF, the open-label Phase 2 portion of this clinical trial to evaluate the safety, tolerability and efficacy of DISC-0974 in patients with anemia of MF." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm)) |
| February 27, 2025 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312525037650/d916827dex991.htm)) |
| March 31, 2025 | [Selcodebart trial start](https://sec-api.dev/pdufa/selcodebart) | IRON |  | completed | "During the three months ended March 31, 2025, the Company dosed the first patient in the Phase 2 clinical trial of DISC-0974." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1816736/000095017025065069/iron-20250331.htm)) |
| May 7, 2025 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000095017025065031/iron-ex99_1.htm)) |
| 2H 2025 | [DISC-3405 trial start](https://sec-api.dev/pdufa/disc-3405) | IRON |  | scheduled | "We expect data from ongoing trials of DISC-0974, the Phase 2 MF anemia study and the Phase 1b NDD-CKD anemia study, to read out in the second half of this year and expect to initiate a Phase 2 study of DISC-3405 in PV in the coming months."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000095017025065031/iron-ex99_1.htm)) |
| August 7, 2025 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000181673625000006/iron-ex99_1.htm)) |
| Sep 2025 | [Bitopertin NDA/BLA submission](https://sec-api.dev/pdufa/bitopertin) | IRON |  | completed | "In September 2025 we submitted a New Drug Application, or NDA, for accelerated approval of bitopertin in EPP and XLP in the United States based on our Phase 2 data." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm)) |
| Oct 2025 | [DISC-3405 trial start](https://sec-api.dev/pdufa/disc-3405) | IRON | SCD in October 2025 with initial data | completed | "Initiated Phase 1b study of DISC-3405 in patients with SCD in October 2025 with initial data expected in 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312525268196/iron-ex99_1.htm)) |
| Q4 2025 | [Selcodebart interim data readout](https://sec-api.dev/pdufa/selcodebart) | IRON | anemia of MF with initial data | scheduled | "Progressing RALLY-MF Phase 2 study of DISC-0974 in patients with anemia of MF with initial data expected in Q4 2025 o" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000181673625000006/iron-ex99_1.htm)) |
| Nov 2025 | [Bitopertin complete response letter (CRL)](https://sec-api.dev/pdufa/bitopertin) | IRON |  | completed, complete response letter | "The U.S. Food and Drug Administration, or the FDA, accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm)) |
| Nov 2025 | [Bitopertin NDA/BLA acceptance](https://sec-api.dev/pdufa/bitopertin) | IRON |  | completed | "The U.S. Food and Drug Administration, or the FDA, accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm)) |
| November 6, 2025 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312525268196/iron-ex99_1.htm)) |
| Dec 2025 | [Disc Medicine, Inc. interim data readout](https://sec-api.dev/companies/iron/catalysts) | IRON |  | scheduled | "We initiated RALLY-MF, the open-label Phase 2 portion of this clinical trial, in December 2024 and we expect to report initial data from this Phase 2 trial at the American Society of Hematology Annual Meeting in December 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1816736/000119312525268200/iron-20250930.htm)) |
| 2026 | [Selcodebart interim data readout](https://sec-api.dev/pdufa/selcodebart) | IRON | anemia of myelofibrosis | scheduled | "Initial data from Phase 2 RALLY-MF trial of DISC-0974 in patients with anemia of myelofibrosis (MF) to be presented at ASH Annual Meeting in December, with topline data expected in 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312525268196/iron-ex99_1.htm)) |
| Q1 2026 | [Selcodebart trial start](https://sec-api.dev/pdufa/selcodebart) | IRON | IBD and anemia | scheduled | "For example, we plan to initiate a Phase 2 clinical trial of DISC-0974 in patients with IBD and anemia in the first quarter of 2026, and we are planning exploratory studies in additional patient populations with anemia of chronic disease." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1816736/000119312525268200/iron-20250930.htm)) |
| 2026 | [DISC-3405 topline data readout](https://sec-api.dev/pdufa/disc-3405) | IRON |  | scheduled | "Topline data from ongoing Phase 2 study in PV expected in 2026" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1816736/000119312525242959/d272031d8k.htm)) |
| February 13, 2026 | [Bitopertin complete response letter (CRL)](https://sec-api.dev/pdufa/bitopertin) | IRON | erythropoietic protoporphyria | completed, complete response letter | "On February 13, 2026, Disc Medicine, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") for the New Drug Application ("NDA") for bitopertin as a treatment for patients with erythropoietic protoporphyria ("EPP")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1816736/000119312526051504/iron-20260213.htm)) |
| February 13, 2026 | [Nda220707 complete response letter (CRL)](https://sec-api.dev/pdufa/nda220707) | IRON |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA220707_20260213.pdf%22)) |
| February 26, 2026 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526073594/iron-ex99_1.htm)) |
| May 5, 2026 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526205187/iron-ex99_1.htm)) |
| Q3 2026 | [DISC-3405 interim data readout](https://sec-api.dev/pdufa/disc-3405) | IRON | polycythemia vera with initial data | scheduled | "Completed enrollment for RESTORE-PV Phase 2 study of DISC-3405 in polycythemia vera (PV) with initial data expected in Q3 2026 and progressing Phase 1b study of DISC-3405 in sickle cell disease (SCD) with initial data expected in Q4 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526325031/iron-ex99_1.htm)) |
| July 30, 2026 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526325031/iron-ex99_1.htm)) |
| late 2026 | [Bitopertin NDA/BLA submission](https://sec-api.dev/pdufa/bitopertin) | IRON |  | scheduled | "Based on these results, the Company plans to resubmit a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") by the end of 2026, with an FDA decision anticipated by mid-2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1816736/000119312526424649/d156263d8k.htm)) |
| September 8, 2026 | [Bitopertin primary completion](https://sec-api.dev/pdufa/bitopertin) | IRON | Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP) | completed | "NCT06910358 (Study of Bitopertin in Participants With EPP or XLP (APOLLO)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-08 (ACTUAL); Lead Sponsor Disc Medicine, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06910358)) |
| Q4 2026 | [Disc Medicine, Inc. topline data readout](https://sec-api.dev/companies/iron/catalysts) | IRON |  | scheduled | "topline data expected Q4 2026 N Size ~150 patients across sites in the US, Canada, Europe, and Australia Trial Duration 6-month treatment period" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526053066/iron-ex99_1.htm)) |
| Q4 2026 | [Selcodebart topline data readout](https://sec-api.dev/pdufa/selcodebart) | IRON |  | scheduled | "Topline data from the RALLY-MF study to be shared in Q4 2026, with an end of Phase 2 meeting with the FDA expected to occur by end of year" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526205187/iron-ex99_1.htm)) |
| Q4 2026 | [DISC-3405 interim data readout](https://sec-api.dev/pdufa/disc-3405) | IRON | SCD in October 2025, with initial data | scheduled | "We also initiated a Phase 1b, open-label clinical trial of DISC-3405 in patients with SCD in October 2025, with initial data expected in the fourth quarter of 2026, and plan to explore the role of therapeutic iron restriction in other indications." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm)) |
| Q4 2026 | [Bitopertin topline data readout](https://sec-api.dev/pdufa/bitopertin) | IRON | Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP) | scheduled | "Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526325031/iron-ex99_1.htm)) |
| Q4 2026 | [Disc Medicine, Inc. topline data readout](https://sec-api.dev/companies/iron/catalysts) | IRON |  | scheduled | "Ongoing Phase 3 APOLLO study potential to serve as basis for traditional approval; topline data anticipated Q4 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526051504/iron-ex99_1.htm)) |
| Q4 2026 | [Disc Medicine, Inc. interim data readout](https://sec-api.dev/companies/iron/catalysts) | IRON | sickle cell disease with initial data | scheduled | "Progressing Phase 1b study in patients with sickle cell disease with initial data expected in Q4 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526325031/iron-ex99_1.htm)) |
| October 2026 | [DISC-0974 primary completion](https://sec-api.dev/pdufa/disc-0974) | IRON | Inflammatory Bowel Disease (IBD); Anemia; Inflammatory Bowel Disease (IBD); Anemia | delayed | "NCT07368972 (Study of DISC-0974-201 in Participants With IBD and Anemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Disc Medicine, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07368972)) |
| Oct 2026 to Jan 2027 | [DISC-0974 topline data readout](https://sec-api.dev/pdufa/disc-0974) | IRON | Inflammatory Bowel Disease (IBD); Anemia; Inflammatory Bowel Disease (IBD); Anemia | scheduled | "NCT07368972 (Study of DISC-0974-201 in Participants With IBD and Anemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Disc Medicine, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07368972)) |
| October 19, 2026 | [Bitopertin topline data readout](https://sec-api.dev/pdufa/bitopertin) | IRON |  | completed, positive | "On October 19, 2026, the Company announced positive topline results from the APOLLO Phase 3 trial of bitopertin in EPP, including X-linked protoporphyria ("XLP")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1816736/000119312526424649/d156263d8k.htm)) |
| November 5, 2026 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526448711/iron-ex99_1.htm)) |
| early 2027 | [Disc Medicine, Inc. topline data readout](https://sec-api.dev/companies/iron/catalysts) | IRON |  | scheduled | "Continue enrollment of the global, confirmatory APOLLO study with topline data expected by early 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526009871/iron-ex99_1.htm)) |
| 2027 | [Selcodebart interim data readout](https://sec-api.dev/pdufa/selcodebart) | IRON | IBD and anemia | scheduled | "Progressing Phase 2 study of selcodebart in patients with inflammatory bowel disease (IBD) with initial data expected in 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526448711/iron-ex99_1.htm)) |
| July 2027 | [DISC-3405 primary completion](https://sec-api.dev/pdufa/disc-3405) | IRON | Polycythemia Vera (PV) | scheduled | "NCT06985147 (A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Disc Medicine, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06985147)) |
| Jul to Oct 2027 | [DISC-3405 topline data readout](https://sec-api.dev/pdufa/disc-3405) | IRON | Polycythemia Vera (PV) | scheduled | "NCT06985147 (A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Disc Medicine, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06985147)) |
| June 2028 | [Bitopertin primary completion](https://sec-api.dev/pdufa/bitopertin) | IRON | Erythropoietic Protoporphyria | scheduled | "NCT05883748 (HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2, PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Disc Medicine, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05883748)) |
| Jun to Sep 2028 | [Bitopertin topline data readout](https://sec-api.dev/pdufa/bitopertin) | IRON | Erythropoietic Protoporphyria | scheduled | "NCT05883748 (HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2, PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Disc Medicine, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05883748)) |

## Drugs

- [Bitopertin](https://sec-api.dev/pdufa/bitopertin): erythropoietic protoporphyria, Erythropoietic Protoporphyria (EPP)
- [DISC-0974](https://sec-api.dev/pdufa/disc-0974): Inflammatory Bowel Disease (IBD)
- [DISC-3405](https://sec-api.dev/pdufa/disc-3405): scd in october 2025, with initial data, polycythemia vera with initial data, pv with initial data, scd in october 2025 with initial data, pv, in june 2025, with initial data, Polycythemia Vera (PV)
- [Nda220707](https://sec-api.dev/pdufa/nda220707): 
- [Selcodebart](https://sec-api.dev/pdufa/selcodebart): ibd and anemia, anemia of mf, inflammatory bowel disease, anemia of mf with initial data, anemia of myelofibrosis, anemia of different inflammatory diseases

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/iron/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IRON catalysts: Disc Medicine, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/iron/catalysts

```bibtex
@misc{secapidev_companies_iron_catalysts_20261116,
  title        = {IRON catalysts: Disc Medicine, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/iron/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_iron_catalysts_20261116","title":"IRON catalysts: Disc Medicine, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/iron/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
